Fig. 7From: Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyProportion of patients remitting from chronic migraine (CM) to episodic migraine (EM) and from medication overuse (MO) to no medication overuse (no-MO). Black bars: patients from headache centers providing data at weeks 12 and 24 (n = 148). Hatched bars: patients from headache centers providing data at weeks 4, 8, 12, 16, 20 and 24 (n = 89)Back to article page